Related Experiment Video

Updated: Feb 19, 2026

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

47.8K

[Mechanisms for castration-resistance of prostate carcinoma]

Fangzhi Chen1, Xiaokun Zhao1

  • 1Department of Urology, Second Xiangya Hospital, Central South University, Changsha 410011, China.

Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences
|November 3, 2017
PubMed

Insights

Prostate cancer can become resistant to hormone therapy. Understanding androgen receptor changes and the tumor microenvironment is key to developing better treatments for castration-resistant prostate cancer (CRPC).

Area of Science:

  • Urology
  • Oncology
  • Molecular Biology

Background:

  • Prostate cancer is a leading male urogenital malignancy.
  • Tumor cells frequently develop castration-resistance after androgen deprivation therapy.
  • Castration-resistant prostate carcinoma (CRPC) poses a significant clinical challenge.

Purpose of the Study:

  • To systematically analyze the mechanisms driving castration-resistance in prostate cancer.
  • To understand the roles of androgen receptor variation and tumor microenvironment changes.
  • To provide a basis for improved precise treatment strategies for CRPC.

Main Methods:

  • Literature review and analysis of existing research on CRPC.
  • Examination of molecular pathways involved in androgen receptor signaling.
  • Investigation of the tumor microenvironment's contribution to treatment resistance.

Main Results:

  • Identified androgen receptor variation and reactivation as critical factors in CRPC development.
  • Highlighted the significant role of tumor microenvironment alterations.
  • Established a link between these factors and the progression to castration-resistance.

Conclusions:

  • Understanding the mechanisms of castration-resistance is crucial for advancing prostate cancer treatment.
  • Targeting androgen receptor pathways and the tumor microenvironment offers potential therapeutic strategies.
  • Further research is needed to refine precise treatment approaches for CRPC.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.1K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K